CVM GFI #237 Oncology Drugs for Companion Animals

Issue Date: August 23, 2017
Issued by: Center for Veterinary Medicine
Topic(s): Investigational New Animal Drug (INAD)
Status: Final

CVM GFI #237 Oncology Drugs for Companion Animals

This guidance document makes recommendations to sponsors of investigational oncology drugs for use in companion animals (e.g., dogs, cats, and horses). The guidance discusses the contents of the target animal safety, effectiveness, and labeling technical sections of a new animal drug application (NADA) for oncology drugs administered as single agents. This guidance also includes recommendations on how to address human user safety concerns. For multi-drug regimens, we recommend that you contact the Center for Veterinary Medicine (CVM) to discuss your product development plan.

Download the Guidance Document

webmaster2026-08-05T19:02:17+00:00

ABOUT US

Avance Biosciences is a leading Contract Research Organization (CRO) and Contract Testing Organization (CTO) providing CGMP and GLP-compliant analytical and bioanalytical services to support drug development. From early discovery through clinical development and commercialization, we provide CGMP and GLP-compliant services tailored to your therapeutic modality and regulatory needs.